Trends in Mergers & Acquisitions

PharmaVentures Business Review is a new cutting-edge television business show that provides viewers with effortless access to essential industry intelligence. As the first of its kind we expect this show to be watched by thousands throughout the pharma and biotech industry, as well as the financial sector.

PharmaVentures Business Review will keep you informed with our insightful coverage of major transactions and industry trends, as well as giving you exclusive access to topical interviews with senior executives and independent expert opinions.

The Month in Review

Covers the following key deals:

• Bayer's acquisition of Schering AG
• Pfizer's acquisition of Rinat Neuroscience
• GlaxoSmithKline's deal with Sirna Therapeutics
• EPIX Pharmaceuticals' merger with Predix Pharmaceuticals
• Infinity Pharmaceuticals' merger with Discovery Partners International

The Business Report

A focus on some of the trends that PharmaVentures' business analysts have observed in the area of Mergers & Acquisitions between 2000 and 2005, using data extracted from PharmaVentures' proprietary deal information resource: PharmaDeals® Agreements.

Face-to-Face

This month's subject is the funding of the Australian biotech industry. To examine the important issues, we have conducted interviews with two key individuals:

• Alison Coutts
  Director of Business Development, eGrowth Capital
• Gavin Rezos
  Chief Executive Officer, pSivida

Meet the Experts

Dr Fintan Walton, CEO of PharmaVentures, leads a discussion with our expert panel on the topic of Mergers & Acquisitions within the biotech and pharmaceutical sector, debating key issues on current trends, key drivers for success and how to avoid the pitfalls.

On the panel this month:

• Charles Macfarlane
  Executive Director Worldwide Alliances, Licensing and Acquisition, Procter & Gamble Company
• Glyn Edwards
  CEO, Antisoma; Deputy Chairman, UK Biotech Industry Association
• Ulrich Kinzel
  Corporate Finance, Nomura Code Securities